4D Molecular’s 4D-150 shows efficacy in Phase 1/2 wet AMD trial

4D Molecular (FDMT) announced positive interim 1.5- to 3.5-year data from the Phase 1/2 PRISM clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration, or wet AMD. 4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-up. Strong dose response in favor of Phase 3 dose – 3E10 vg/eye – continues to be demonstrated. 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings, consistent with previous updates, with up to 3.5 years of follow-up. 4FRONT-1 Phase 3 enrollment continues to exceed initial expectations, with over 200 patients randomized to date; the global 4FRONT-2 Phase 3 clinical trial enrollment remains on track for expected completion in H2 2026.